Login / Signup

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.

Bruno VincenziMike TrowerAjay DuggalPamela GuglielminiPeter HarrisDavid JacksonMario E LacoutureEmiliangelo RattiGiuseppe ToniniAndrew Wood
Published in: BMJ open (2020)
EudraCT2013-002763-25.
Keyphrases
  • placebo controlled
  • double blind
  • open label
  • study protocol
  • phase ii
  • phase iii
  • clinical trial
  • high glucose
  • phase ii study
  • diabetic rats
  • randomized controlled trial
  • endothelial cells